Sugi Predict

Sugi Predict / Compounds / SCHEMBL4891665

SCHEMBL4891665

SCHEMBL4891665

CC(=O)[C@@](O)(C(=O)O)[C@@](O)(C(C)=O)C(=O)O

nearest known ligand 0.47

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 4/20 0.47
▸ ALDH1A1 P00352 3/20 0.47
▸ FFAR3 O14843 1/20 0.40
▸ LCK P06239 1/20 0.40
▸ FYN P06241 1/20 0.40
▸ LMNA P02545 1/20 0.33
▸ TP53 P04637 1/20 0.33
▸ HMGCR P04035 1/20 0.32
▸ CHRM1 P11229 1/20 0.32
▸ TBXA2R P21731 1/20 0.32
▸ ADRA1A P35348 1/20 0.32
▸ TRPA1 O75762 1/20 0.32
▸ THPO P40225 1/20 0.31
▸ CYP2D6 P10635 1/20 0.30
▸ CYP2C19 P33261 1/20 0.30
▸ HIF1A Q16665 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30868398 1.00 TSHR (0.47) TSHRALDH1A1FFAR3LCKFYN
SCHEMBL30167444 1.00 TSHR (0.47) TSHRALDH1A1FFAR3LCKFYN
SCHEMBL1323784 1.00 TSHR (0.47) TSHRALDH1A1FFAR3LCKFYN
Ammonia Solution, Strong SCHEMBL1333561 0.97 ALDH1A1 (0.44) TSHRALDH1A1FFAR3LCKFYN
Glycerin SCHEMBL3981872 0.82 ALDH1A1 (0.43) TSHRALDH1A1LMNA
SCHEMBL354063 0.81 LMNA (0.42) TSHRALDH1A1FFAR3LCKFYN
SCHEMBL10949463 0.71 TSHR (0.56) TSHRALDH1A1FFAR3LCKFYN
SCHEMBL1965420 0.69 — —
SCHEMBL7644443 0.69 ALDH1A1 (0.37) TSHRALDH1A1LMNAHMGCRCHRM1
SCHEMBL7525703 0.69 LMNA (0.31) TSHRALDH1A1LMNATRPA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024075131-A1 CO-CRYSTAL OF UPADACITINIB AND DIACETYL-D-TARTARIC ACID AND PROCESS FOR THE PREPARATION THEREOF NATCO PHARMA LIMITED (IN) 2024-04-11 — — WO claimed
CN-107778234-B Preparation method of neuromuscular blocker intermediate 四川科瑞德制药股份有限公司 2023-01-06 — — CN claimed
CN-114716375-A Preparation method of tetrahydrobenzyl isoquinoline compound 四川科瑞德制药股份有限公司 2022-07-08 — — CN claimed
WO-2024075131-A1 CO-CRYSTAL OF UPADACITINIB AND DIACETYL-D-TARTARIC ACID AND PROCESS FOR THE PREPARATION THEREOF NATCO PHARMA LIMITED (IN) 2024-04-11 — — WO disclosed
WO-2024075131-A1 CO-CRYSTAL OF UPADACITINIB AND DIACETYL-D-TARTARIC ACID AND PROCESS FOR THE PREPARATION THEREOF NATCO PHARMA LIMITED (IN) 2024-04-11 — — WO disclosed
WO-2024075131-A1 CO-CRYSTAL OF UPADACITINIB AND DIACETYL-D-TARTARIC ACID AND PROCESS FOR THE PREPARATION THEREOF NATCO PHARMA LIMITED (IN) 2024-04-11 — — WO disclosed
CN-113620876-B Synthesis method of 5' -methoxy laudan 广东嘉博制药有限公司 2024-02-13 — — CN disclosed
CN-113480480-B Synthesis method of (R) -5' -methoxy laudan 广东嘉博制药有限公司 2024-02-13 — — CN disclosed
WO-2023086696-A2 APPARATUS AND METHODS FOR CONTINUOUS FLOW SYNTHESIS OF CISATRACURIUM ODH IP Corp. (US) 2023-05-19 — — WO disclosed
CN-107778234-B Preparation method of neuromuscular blocker intermediate 四川科瑞德制药股份有限公司 2023-01-06 — — CN disclosed
CN-114716375-A Preparation method of tetrahydrobenzyl isoquinoline compound 四川科瑞德制药股份有限公司 2022-07-08 — — CN disclosed
US-8329714-B2 Farnesyl transferase inhibiting 1,2-annelated quinoline enantiomer JANSSEN PHARMACEUTICA NV (BE) 2012-12-11 — — US disclosed
US-8318753-B2 (-)-5-(3-Chlorophenyl)- alpha -(4-chlorophenyl)- alpha -(1-methyl-1H-imidazol-5-yl)tetrazolo-[1,5-a]quinazoline-7-methanamine and its pharmaceutically acceptable acid addition salts; anticancer agent JANSSEN PHARMACEUTICA NV (BE) 2012-11-27 — — US disclosed
US-20080114009-A1 Farnesyl Transferase Inhibiting 1,2-Annelated Quinoline Enantiomer VENET MARC GASTON 2008-05-15 — — US disclosed
US-20070259902-A1 FARNESYL TRANSFERASE INHIBITING 1,2-ANNELATED QUINOLINE ENANTIOMER VENEL MARC G 2007-11-08 — — US disclosed
EP-1296984-B1 PHARMACEUTICAL COMPOSITION COMPRISING A FARNESYL TRANSFERASE INHIBITING 1,2-ANNELATED QUINOLINE ENANTIOMER JANSSEN PHARMACEUTICA NV (BE) 2005-05-04 — — EP disclosed
US-20030114471-A1 Farnesyl transferase inhibiting 1,2-annelated quinoline enantiomer JANSSEN PHARMACEUTICA N.V. (BE) 2003-06-19 — — US disclosed
EP-1296984-A1 FARNESYL TRANSFERASE INHIBITING 1,2-ANNELATED QUINOLINE ENANTIOMER JANSSEN PHARMACEUTICA N.V. (BE) 2003-04-02 — — EP disclosed
WO-2001098302-A1 FARNESYL TRANSFERASE INHIBITING 1,2-ANNELATED QUINOLINE ENANTIOMER JANSSEN PHARMACEUTICA N.V. (BE) 2001-12-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030114471-A1 Farnesyl transferase inhibiting 1,2-annelated quinoline enantiomer FNTB, FNTA, CYP7A1 TSHR 3679/4885ALDH1A1 317/4885FFAR3 2790/4885
US-20070259902-A1 FARNESYL TRANSFERASE INHIBITING 1,2-ANNELATED QUINOLINE ENANTIOMER FNTA, FNTB, CYP7A1 TSHR 3648/4885ALDH1A1 276/4885FFAR3 2561/4885
US-20080114009-A1 Farnesyl Transferase Inhibiting 1,2-Annelated Quinoline Enantiomer FNTA, FNTB, CYP7A1 TSHR 3648/4885ALDH1A1 276/4885FFAR3 2561/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.